RATIONALE: Several studies have suggested that nicotine treatment can modulate the behavioral and neurochemical responses to other psychostimulants, such as cocaine. OBJECTIVES: The current study examined the hypothesis that nicotinic acetylcholine receptor (nAChR) blockade influences the ability of cocaine to elicit increases in extracellular dopamine levels. MATERIALS AND METHODS: Pharmacological studies using nicotinic antagonists as well as genetic inactivation of beta2* nAChRs were used to determine the effect of nAChR blockade on dopamine levels in ventral striatum elicited by acute or repeated administrations of cocaine in mice. RESULTS: Administration of mecamylamine (a general nicotinic antagonist that is not highly selective for individual nAChR subtypes) or co-administration of methyllycaconitine (a more selective antagonist of alpha7* nAChRs) with dihydro-beta-erythroidine (a more selective antagonist of beta2* nAChRs and other heteromeric nAChR subtypes) prevented sensitization of cocaine-elicited increases in extracellular DA levels in the ventral striatum in wild-type mice. In contrast, neither of the more specific antagonists alone was effective in preventing sensitization. Finally, methyllycaconitine administration prevents sensitization in beta2-/- mice but not in beta2+/+ or wild-type mice. CONCLUSIONS: These data indicate that inhibition of both alpha7* and beta2* nAChRs is necessary to prevent development of sensitization of cocaine-elicited increases in extracellular dopamine levels in the ventral striatum of mice.
RATIONALE: Several studies have suggested that nicotine treatment can modulate the behavioral and neurochemical responses to other psychostimulants, such as cocaine. OBJECTIVES: The current study examined the hypothesis that nicotinic acetylcholine receptor (nAChR) blockade influences the ability of cocaine to elicit increases in extracellular dopamine levels. MATERIALS AND METHODS: Pharmacological studies using nicotinic antagonists as well as genetic inactivation of beta2* nAChRs were used to determine the effect of nAChR blockade on dopamine levels in ventral striatum elicited by acute or repeated administrations of cocaine in mice. RESULTS: Administration of mecamylamine (a general nicotinic antagonist that is not highly selective for individual nAChR subtypes) or co-administration of methyllycaconitine (a more selective antagonist of alpha7* nAChRs) with dihydro-beta-erythroidine (a more selective antagonist of beta2* nAChRs and other heteromeric nAChR subtypes) prevented sensitization of cocaine-elicited increases in extracellular DA levels in the ventral striatum in wild-type mice. In contrast, neither of the more specific antagonists alone was effective in preventing sensitization. Finally, methyllycaconitine administration prevents sensitization in beta2-/- mice but not in beta2+/+ or wild-type mice. CONCLUSIONS: These data indicate that inhibition of both alpha7* and beta2* nAChRs is necessary to prevent development of sensitization of cocaine-elicited increases in extracellular dopamine levels in the ventral striatum of mice.
Authors: P Whiteaker; M J Marks; S R Grady; Y Lu; M R Picciotto; J P Changeux; A C Collins Journal: Eur J Pharmacol Date: 2000-03-30 Impact factor: 4.432
Authors: Valentina Licheri; Oona Lagström; Amir Lotfi; Mary H Patton; Holger Wigström; Brian Mathur; Louise Adermark Journal: J Neurosci Date: 2018-06-25 Impact factor: 6.167
Authors: Wojciech Solecki; Robert J Wickham; Shay Behrens; Jie Wang; Blake Zwerling; Graeme F Mason; Nii A Addy Journal: Neuropharmacology Date: 2013-07-11 Impact factor: 5.250
Authors: Taline V Khroyan; Dennis Yasuda; Lawrence Toll; Willma E Polgar; Nurulain T Zaveri Journal: Biochem Pharmacol Date: 2015-08-07 Impact factor: 5.858
Authors: Edward D Levin; Ann Petro; Amir H Rezvani; Ninitia Pollard; N Channelle Christopher; Mariel Strauss; Jessica Avery; Jessica Nicholson; Jed E Rose Journal: Behav Brain Res Date: 2008-09-11 Impact factor: 3.332